Navigation Links
Anthera's Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
Date:5/6/2009

isk patients) and maintained this lower level throughout the primary endpoint. The effect was more pronounced for patients achieving LDL-C below 50 mg/dL.

"Building on strong results from our first two clinical studies in stable cardiovascular patients, the FRANCIS study has validated the potential utility of aggressive varespladib treatment to improve outcomes in a high-risk patient population immediately following an ACS event," said Paul F. Truex, President and Chief Executive Officer of Anthera Pharmaceuticals, Inc. "In addition to meeting the primary and several secondary endpoints, clinical data from the FRANCIS study has met and/or exceeded our expectations and we hope to present the entire data set including biomarkers, safety, and secondary clinical endpoints (MACE) at an upcoming scientific conference."

"We are extremely excited by these data," said Colin Hislop, M.D., Senior Vice President Clinical Development at Anthera. "The favorable treatment effect of varespladib is consistent with our Phase 3 development plan and provides a robust data set to support substantial clinical benefit for this novel, first in class therapy."

With approximately 1000 patient exposures to date in three cardiovascular studies, varespladib has been generally well tolerated.

About the FRANCIS trial

The FRANCIS trial is based upon direct feedback from Food and Drug Administration via the Special Protocol Assessment process. FRANCIS was designed to assess the impact of oral varespladib on known biological markers of cardiovascular risk. It enrolled 625 patients who will be treated for a minimum of six months. The study is being conducted at sites in Europe. FRANCIS is designed to provide insight into the potential prevention of secondary Major Adverse Cardiovascular Events (MACE) by varespladib. In this study, MACE was defined as a composite endpoint consisting of all-cause mortali
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
2. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
3. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
4. Schering-Ploughs Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
5. Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant
6. Alexzas AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial
7. TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
8. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
9. NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
10. Alexzas AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients
11. Teliks Proteasome Inhibitor Program Meets a Preclinical Development Milestone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014  The Chemistry, Food ... Ministry of Health approved the introduction of Telaprevir ... the cure rate from Hepatitis C, and it ... 1 virus. Telaprevir is available in ... Photo - http://www2.prnewswire.com.br/imgs/pub/2014-07-25/original/2026.jpg   ...
(Date:7/25/2014)... July 25, 2014  Solanbridge Group Inc (OTC: SLNX) ... majority interest in Buzznbrewz.com and the Letter of Intent ... a fully executed Purchase Agreement. Charles ... are proud to have Mr. David Pecoraro ... experience in the private sector and developed a tremendous ...
(Date:7/25/2014)... July 25, 2014 Research and Markets ... Ophthalmic Diagnostic Devices Market 2014-2018" report to their ... About Ophthalmic Diagnostic Device An ... identify a defect or deficiency in the human visual ... disorders such as presbyopia, cataracts, glaucoma, retinal disorders, conjunctivitis, ...
Breaking Medicine Technology:The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3Solanbridge Group Inc Announces Acquisition of Buzznbrewz.com 2Global Ophthalmic Diagnostic Devices Market 2014-2018: Key Vendors are Alcon, Carl Zeiss, Haag-Streit and Topcon 2
... Results of Largest Randomized, Placebo-controlled Trial,Ever Conducted ... of,Clinical Oncology, CHICAGO, June 04, 2007 /PRNewswire/ ... clinical trial ever,conducted in patients with cutaneous ... than twice as effective as placebo in ...
... in Patients With Follicular Lymphoma Reported,Today at ... /PRNewswire/ -- GlaxoSmithKline plc,announced today long-term efficacy ... a,single one-week course of frontline treatment with ... Tositumomab) in,76 patients with newly diagnosed advanced ...
Cached Medicine Technology:Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 2Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 3Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 4Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 5Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 68-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 28-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 38-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 48-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 58-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 68-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 7
(Date:7/28/2014)... 2014 Scientists in Japan have completed ... blood test for the asbestos cancer mesothelioma. Surviving Mesothelioma ... Click here to read it now. , ... Juntendo University Graduate School of Medicine say a new ... step above the old test. , “Particularly for ...
(Date:7/28/2014)... July 28, 2014 Maternal and Family ... Tucker Award, which will be presented at the agency’s ... October 29th at the Westmoreland Club in Wilkes-Barre. , ... Commissioner and long-time employee of MFHS. She dedicated ... political activist, health advocate, and champion for women, children ...
(Date:7/28/2014)... that following a healthy lifestyle may lower childhood cancer ... online in CANCER , a peer-reviewed journal of ... with cancer and adults who had cancer when they ... may influence their long-term health. , Adults who ... increased risk for the metabolic syndrome, a group of ...
(Date:7/28/2014)... As health insurers design their strategies ... exchanges. “Private Exchange Strategies for Insurers: What’s Working? ... Information Services, will provide answers to the big-dollar questions ... future. , Barbara Gniewek, Jonathan Har-Even and Martin Hill ... the private exchange sector — will provide expert presentations ...
(Date:7/28/2014)... GA (PRWEB) July 28, 2014 Mitul ... the nation gathered at the MGE Management Experts Benefit ... and community leaders joined the Dentists to raise funds ... the Boys and Girls Clubs and Youth Programs across ... of young people with books and audio books to ...
Breaking Medicine News(10 mins):Health News:Test Results Look Promising for New Mesothelioma Blood Test, According to Surviving Mesothelioma 2Health News:MFHS Seeking Nominations for Rose Allan Tucker Award 2Health News:Lifestyle choices may affect the long-term heart health of childhood cancer survivors 2Health News:Three PwC Consultants to Offer Insurers Successful Strategies for Private Exchanges 2Health News:Mitul R. Patel, DDS Successfully Attacks a Major Source of Economic Destruction in the Battle Against Illiteracy and Poverty 2Health News:Mitul R. Patel, DDS Successfully Attacks a Major Source of Economic Destruction in the Battle Against Illiteracy and Poverty 3
... Results from two,studies comparing colorectal cancer screening ... called virtual colonoscopy),have sparked interest in colorectal cancer ... consumers. The studies, one a large multi-center,trial sponsored ... other from the,University of Wisconsin published in the ...
... Health COO First Annual Honoree, SOMERSET, N.J., Oct. ... (Nasdaq: VTIV ) and President and CEO,of inVentiv ... Big,Brothers Big Sisters(R) (BBBS) of Hunterdon & Somerset Counties ... Moments, Big Magic -- A,Match That Lights an Eternal ...
... Liver, NEW YORK, Oct. 5 Urging every ... (ALF) today observed Liver,Awareness Month by releasing 12 tips ... Liver disease, a serious and largely unrecognized problem in ... among adults between the ages of,25 and 64, taking ...
... month a collaboration of European and Asian researchers launched ... harnessing the combined power of more than 40,000 computers ... drug discovery. , Called Enabling Grids for E-sciencE, the ... supercomputer that is being used during this challenge to ...
... Tenn., Oct. 5 Emdeon Business Services,announced ... Delta Dental payers for,insurance eligibility and benefits ... vendor partners and through the Emdeon suite ... Provider Services,(DPS), Emdeon,s interactive web portal. Emdeon ...
... Mich., Oct. 5 Volkswagen of America,Inc., in ... Volkswagen,dealers, proudly announces its 12th consecutive year of ... delighted to continue our sponsorship for our 12th ... "The LaSalle Bank,Chicago Marathon is a great opportunity ...
Cached Medicine News:Health News:Frequently Asked Questions When Considering a Colorectal Cancer Screening Test, From the American College of Gastroenterology 2Health News:Frequently Asked Questions When Considering a Colorectal Cancer Screening Test, From the American College of Gastroenterology 3Health News:Terrell Herring Honored by Big Brothers Big Sisters 2Health News:October is Liver Awareness Month: The American Liver Foundation Urges All Americans to Pay Attention to Their Liver Every Day of the Year 2Health News:October is Liver Awareness Month: The American Liver Foundation Urges All Americans to Pay Attention to Their Liver Every Day of the Year 3Health News:Grid computing offers new hope in race against bird flu 2Health News:Emdeon Business Services Extends Market Leadership With New Dental Eligibility Payers 2Health News:Volkswagen Continues Sponsorship of the Lasalle Bank Chicago Marathon 2
... PROXIMATE Access 55 Articulating Linear Staplers are ... or a thick-tissue green instrument (non-reloadable). Each ... 55mm staple line., ,Benefits include: , ... in narrow male pelvis. , Articulating head ...
... Staplers deliver two staggered rows of titanium staples ... be reloaded up to three times for a ... wire staples for thick tissue. The TLV model ... ,Benefits include: , Parallel jaw closure ensures that ...
... Loading Units With Titanium Staples ... TA™ (Single Use Reloadable Stapler ... Auto Suture™ PREMIUM MULTIFIRE TA™ ... gynecological, pediatric and thoracic surgical ...
Single Use Reloadable Stapler with Titanium Staples., ,The Auto Suture™ PREMIUM MULTIFIRE TA™ stapler has applications in abdominal, gynecological, pediatric and thoracic surgical proced...
Medicine Products: